Phio Pharmaceuticals
PHIO
4 hedge funds and large institutions have $3.14M invested in Phio Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
3% more capital invested
Capital invested by funds: $3.06M → $3.14M (+$81K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$251K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$251K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$28K |
| 3 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$12K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8K |
PHIO Hedge Fund Activity: Q4 2015 in Review
4 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2015, worth a combined $3.14M — up 2.7% from $3.06M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PHIO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $251K. The largest seller was Broadfin Capital, cutting an estimated $251K.
- 4 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2015, up from 3 in Q3 2015.
- Funds reported $3.14M of Phio Pharmaceuticals stock for Q4 2015, up 2.7% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q4 2015 and 0 closed out, a net change of +1 holder.
- The largest Phio Pharmaceuticals buyer in Q4 2015 was Anson Funds Management, an estimated $251K added.
- The largest Phio Pharmaceuticals seller in Q4 2015 was Broadfin Capital, an estimated $251K sold.
Based on aggregated 13F filings for Q4 2015.